Table 3.
Diseases | Toxicological Effects | AN Components | Mechanism | Biological Materials | References |
---|---|---|---|---|---|
Oral | dysregulating proinflammatory cytokines | AN | ↓ TGF-β | human | [89] |
low prevalence of oral submucous fibrosis | human | [90] | |||
deteriorate prognosis of oral cancer | AN | human | [91] | ||
oral carcinogenesis | 0.35% AN extract | ↑ AP-1, apoptotic gnes, ↓ cell cycle regulators |
KB cells | [92] | |
initiate oral submucous fibrosis process | Arecoline | human | [93] | ||
reactive oxygen species ↑, cell cycle arrest, apoptosis ↓, DNA damage | 800 μg/mL Arecoline | OSCC cells | [94] | ||
induce oral pathologies mechanisms | Arecoline | ↑ MAPK, PI3K Akt, NF-κB, PKC pathways | [95] | ||
promote metastasis of oral cancer | 160 μg/mL Arecoline | cytokines for EMT | CAL33 and UM2 cells | [96] | |
promoted buccal mucosal fibroblasts | 20 and 50 µg/mL Arecoline | ↑ TGF-β | buccal mucosal fibroblasts | [98] | |
increased oxidative stress | AN | ↓ reductase, superoxide and dismutase, ↑ micronuclei in buccal exfoliated cells |
human | [99] | |
carcinogenesis not found in animal models | Arecoline | [100] | |||
Liver | risk factor for various liver diseases | AN | human | [4] | |
promoting migration and proliferation of human HepG2 cells | 2.5 µM Arecoline | ↑ PI3K-AKT pathway | HepG2 cells | [101] | |
associated with liver fibrosis | AN | human | [102] | ||
high risk of liver fibrosis | AN | human | [103] | ||
Behavior and Addiction | behavioral alterations | 0.001, 0.01, 0.1, or 1 ppm four alkaloid | zebrafish | [19] | |
increase sense of well-being, stamina, and euphoria | AN | human | [104] | ||
antidepressant | 10 mg/kg Dichloromethane fraction | ↓ monoamine oxidase-A | rat brain | [105] | |
addiction of AN | AN | human | [106] | ||
methods for AN cessation | AN | human | [104] | ||
emerging pharmacological cessation therapies | AN | human | [11] | ||
Cardiac | cardiac apoptosis | 5 and 50 mg/kg/day arecoline | ↑ Fas/Fas ligand pathway | rats | [108] |
cardiotoxicity and heart damage | 5 and 50 mg/kg/day arecoline | ↑ JAK2/STAT3, MEK5/ERK5, MAPK pathways | rats | [109] | |
cardiac fibrosis | 5 and 50 mg/kg/day arecoline | ↑ TGF-β)/Smad pathways | rats | [110] | |
Gastric and intestinal | developed gastric cancer | 1 mg raw areca nutt | ↑ histone H3 epigenetic modifications and Rb/E2F1 pathway | mice | [111] |
decreases intestinal epithelial cell lining functions | AN extract | ↓ membrane constituents | rats | [112] | |
Genotoxicity | genetic toxicology | Arecoline | ↑ gene mutations, DNA damage and repair, cytogenetic effects | in vitro, in vivo | [17] |
Reproduction and development | risk factor for preterm birth | AN | ↑ oxidative stress | human | [113] |
low birth weight | AN | human | [114] | ||
inducing oocyte apoptosis | 160, 180 and 200 μg/mL arecoline | ↑ oxidative stress | mouse oocytes | [115] | |
Inhibiting myogenesis | 0.04 and 0.08 mM arecoline | ↓ pStat3 | C2C12 cells | [116] | |
defective effects of myogenesis | 0.04 and 0.08 mM arecoline | ↓ myosin heavy chain, myogenin | C2C12 cells | [117] | |
Kidney | high risk of kidney stone disease | >30 AN quids | human | [118] | |
promoting the progression of chronic kidney disease | 10, 20, or 40 μg/mL arecoline | ↑ EMT genes, fibrogenesis markers | HK2 cells | [119] | |
Neuron activation | nicotine addiction | 100 µM four areca alkaloid | ↑ nAChR | Xenopus oocytes | [120] |
Abortifacient | may have abortifacient effects | AN | human | [121] |
↑: Activated, ↓: Inhibited, AN: partial or whole AN chewing.